人类免疫缺陷病毒1型早期慢性感染期间中和抗体反应拓宽过程中的主要病毒包膜交叉反应性
Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.
作者信息
Zhang P F, Chen X, Fu D W, Margolick J B, Quinnan G V
机构信息
Department of Preventive Medicine and Biometrics, Division of Tropical Public Health, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA.
出版信息
J Virol. 1999 Jun;73(6):5225-30. doi: 10.1128/JVI.73.6.5225-5230.1999.
Abstract
To test the hypothesis that changing neutralizing antibody responses against human immunodeficiency virus type 1 (HIV-1) during chronic infection were a response to emergence of neutralization escape mutants, we cloned expressed and characterized envelope clones from patients in the Multicenter AIDS Cohort Study (MACS). Pseudotyped HIV-1 envelope clones obtained from differing time points were assessed for sensitivity to neutralization by using sera from different times from the same and different patients. Clones from early and late time points during chronic infection had similar neutralization sensitivity, and neutralizing antibody responses cross-reacted with early, late, and heterologous envelopes. The potential for broadly effective HIV-1 immunization is supported.
摘要
为了验证慢性感染期间针对1型人类免疫缺陷病毒（HIV-1）的中和抗体反应变化是对中和逃逸突变体出现的反应这一假设，我们在多中心艾滋病队列研究（MACS）中克隆、表达并鉴定了来自患者的包膜克隆。使用来自同一患者和不同患者不同时间的血清，评估从不同时间点获得的假型HIV-1包膜克隆的中和敏感性。慢性感染早期和晚期时间点的克隆具有相似的中和敏感性，并且中和抗体反应与早期、晚期和异源包膜发生交叉反应。这支持了广泛有效的HIV-1免疫的可能性。
相似文献
1
Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.人类免疫缺陷病毒1型早期慢性感染期间中和抗体反应拓宽过程中的主要病毒包膜交叉反应性
J Virol. 1999 Jun;73(6):5225-30. doi: 10.1128/JVI.73.6.5225-5230.1999.
2
A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.可变区3（V3）突变决定了一种与广泛交叉反应的原发性病毒中和抗体反应相关的人类免疫缺陷病毒1型包膜的整体中和表型和不依赖CD4的感染性。
J Virol. 2002 Jan;76(2):644-55. doi: 10.1128/jvi.76.2.644-655.2002.
3
Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.1型人类免疫缺陷病毒的V1-V2包膜环序列在感染过程中会扩展并增加糖基化位点，这些修饰会影响抗体中和敏感性。
J Virol. 2006 Oct;80(19):9586-98. doi: 10.1128/JVI.00141-06.
4
Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.对人类免疫缺陷病毒1型A亚型和B亚型V3结构域具有交叉反应性的抗体在喀麦隆患者血清中很常见，但其中和活性通常受到表位掩盖的限制。
J Virol. 2005 Jan;79(2):780-90. doi: 10.1128/JVI.79.2.780-790.2005.
5
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.在对第二个高变区进行部分缺失后，一种寡聚体1型人类免疫缺陷病毒（HIV-1）包膜抗原引发针对原发性HIV-1分离株的中和抗体的能力得到了提高。
J Virol. 2001 Jun;75(12):5526-40. doi: 10.1128/JVI.75.12.5526-5540.2001.
6
Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.用于标准化中和评估的HIV-1 C亚型Env参考毒株组
J Virol. 2017 Sep 12;91(19). doi: 10.1128/JVI.00991-17. Print 2017 Oct 1.
7
Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection.中和抗体及抗体依赖性细胞介导的细胞毒性在人类免疫缺陷病毒感染中的潜在有益作用。
AIDS Res Hum Retroviruses. 1990 Mar;6(3):341-56. doi: 10.1089/aid.1990.6.341.
8
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.1型人类免疫缺陷病毒感染个体初次血清转化后的自体和异体中和抗体反应。
J Virol. 1997 May;71(5):3734-41. doi: 10.1128/JVI.71.5.3734-3741.1997.
9
Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.HIV-1血清交叉谱系反应性和中和作用的二分法：对主动和被动免疫疗法的启示。
J Med Virol. 2005 Jun;76(2):146-52. doi: 10.1002/jmv.20339.
10
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.利用源自甲病毒的体内表达系统在小动物中诱导产生原发性病毒交叉反应性1型人类免疫缺陷病毒中和抗体
J Virol. 2003 Mar;77(5):3119-30. doi: 10.1128/jvi.77.5.3119-3130.2003.
引用本文的文献
1
Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.格里菲斯菌素修饰的电纺纤维作为预防HIV感染的递送支架
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6518-6531. doi: 10.1128/AAC.00956-16. Print 2016 Nov.
2
Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.人类免疫缺陷病毒 1 型单价或三价包膜糖蛋白诱导的猕猴中和抗体反应。
PLoS One. 2013;8(3):e59803. doi: 10.1371/journal.pone.0059803. Epub 2013 Mar 22.
3
Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.高效利用单一株病毒载体在本氏烟植物中生物生产广泛中和抗 HIV-1 单克隆抗体 VRC01 及其在组合型杀微生物剂中的应用
Antimicrob Agents Chemother. 2013 May;57(5):2076-86. doi: 10.1128/AAC.02588-12. Epub 2013 Feb 12.
4
Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.利用委内瑞拉马脑炎病毒体内表达系统诱导中和抗 Hendra 和 Nipah 糖蛋白抗体。
Vaccine. 2010 Dec 16;29(2):212-20. doi: 10.1016/j.vaccine.2010.10.053. Epub 2010 Nov 2.
5
Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses.同时期血浆病毒所表达的HIV-1包膜蛋白的功能多样性。
Retrovirology. 2008 Feb 29;5:23. doi: 10.1186/1742-4690-5-23.
6
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization.由gp140免疫诱导产生的广泛交叉反应性抗HIV-1中和抗体。
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10193-8. doi: 10.1073/pnas.0608635104. Epub 2007 May 31.
7
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.剖析来自1型人类免疫缺陷病毒感染供体的广泛中和血清的中和抗体特异性。
J Virol. 2007 Jun;81(12):6548-62. doi: 10.1128/JVI.02749-06. Epub 2007 Apr 4.
8
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.恒河猴对低致病性猿猴-人类免疫缺陷病毒感染的保护作用：与中和抗体和细胞毒性T细胞的相关性
J Virol. 2005 Mar;79(6):3358-69. doi: 10.1128/JVI.79.6.3358-3369.2005.
9
Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.源自1型人类免疫缺陷病毒R2株的独特V3环序列可引发广泛的中和抗体。
AIDS Res Hum Retroviruses. 2004 Nov;20(11):1259-68. doi: 10.1089/aid.2004.20.1259.
10
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.一种新型交叉反应性1型人类免疫缺陷病毒中和性人单克隆抗体的鉴定与表征
J Virol. 2004 Sep;78(17):9233-42. doi: 10.1128/JVI.78.17.9233-9242.2004.
本文引用的文献
1
Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.gp120和gp41中的突变导致了1型变异人类免疫缺陷病毒MN对针对V3和非V3表位的抗体产生广泛的中和抗性。
J Virol. 1998 Sep;72(9):7099-107. doi: 10.1128/JVI.72.9.7099-7107.1998.
2
Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants.多中心艾滋病队列研究参与者中针对1型人类免疫缺陷病毒病毒体和假病毒的中和抗体反应的演变
AIDS Res Hum Retroviruses. 1998 Jul 20;14(11):939-49. doi: 10.1089/aid.1998.14.939.
3
Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).麻疹、腮腺炎和风疹——疫苗使用及消除麻疹、风疹和先天性风疹综合征并控制腮腺炎的策略：免疫实践咨询委员会（ACIP）的建议
MMWR Recomm Rep. 1998 May 22;47(RR-8):1-57.
4
Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry.基因差异的猿猴免疫缺陷病毒株将CCR5用作进入细胞的共受体。
J Virol. 1997 Apr;71(4):2705-14. doi: 10.1128/JVI.71.4.2705-2714.1997.
5
Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.1型人类免疫缺陷病毒对天然抗血清中和作用的抗性是通过单个氨基酸取代发生的，这些取代会导致多个位点的抗体结合发生变化。
J Virol. 1996 Dec;70(12):8431-7. doi: 10.1128/JVI.70.12.8431-8437.1996.
6
Identification of a major co-receptor for primary isolates of HIV-1.HIV-1 原代分离株主要共受体的鉴定。
Nature. 1996 Jun 20;381(6584):661-6. doi: 10.1038/381661a0.
7
Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection.抗体识别的精细特异性可能预示着1型人类免疫缺陷病毒（HIV-1）感染期间gp120第三可变区的氨基酸替换。
AIDS Res Hum Retroviruses. 1995 Oct;11(10):1153-62. doi: 10.1089/aid.1995.11.1153.
8
Immune escape and tropism of HIV.HIV的免疫逃逸与嗜性
Trends Microbiol. 1995 Sep;3(9):356-61. doi: 10.1016/s0966-842x(00)88975-1.
9
Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.人类免疫缺陷病毒1型gp41的突变会影响其对gp120抗体中和作用的敏感性。
J Virol. 1993 Nov;67(11):6897-902. doi: 10.1128/JVI.67.11.6897-6902.1993.
10
Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype.人类免疫缺陷病毒1型的两种抗原性不同的亚型：病毒基因型可预测中和血清型。
J Infect Dis. 1994 Jan;169(1):48-54. doi: 10.1093/infdis/169.1.48.
Zotero 插件